Quarterly report · Q2
4671.TEDINET S100PKQ2
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥24.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥50.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥24.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥3.1bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.3bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.3bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥2.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥38.7bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥40.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥39.1bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥14.4bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥16.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥24.3bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥23.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥22.4bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.9bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.9bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.1bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.6bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥249m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥503m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥937m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥107.5 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.16 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥339 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥204.38 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥122.9 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥107.18 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥336.99 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥203.77 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 62.6% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.1% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.1% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥4m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥213m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥16.2bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥16.2bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.6bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥320m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥24.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥24.2bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥8m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥8m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥177m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥16.6bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥16.6bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥7m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥8.1bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥8.1bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥523m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥24.7bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥24.7bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥8m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥3.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 519
| Item | Context | Value | Unit |
|---|---|---|---|
| Income taxes paid ope cf | Prior1YTDDuration | -784000000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -1271000000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 2036000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 1451000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -350000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -350000000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -32000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -43000000 | JPY |
| Proceeds from transfer of business inv cf | Prior1YTDDuration | 16000000 | JPY |
| Proceeds from transfer of business inv cf | CurrentYTDDuration | － | JPY |
| Purchase of investment securities inv cf | Prior1YTDDuration | -107000000 | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | -231000000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1YTDDuration | － | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYTDDuration | 372000000 | JPY |
| Proceeds from collection of guarantee deposits inv cf | Prior1YTDDuration | 158000000 | JPY |
| Proceeds from collection of guarantee deposits inv cf | CurrentYTDDuration | 16000000 | JPY |
| Payments for guarantee deposits inv cf | Prior1YTDDuration | － | JPY |
| Payments for guarantee deposits inv cf | CurrentYTDDuration | -4000000 | JPY |
| Other net inv cf | Prior1YTDDuration | -187000000 | JPY |
| Other net inv cf | CurrentYTDDuration | -9000000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -503000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -249000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | -250000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | -100000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -390000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -383000000 | JPY |
| Repayments of finance lease obligations fin cf | Prior1YTDDuration | -141000000 | JPY |
| Repayments of finance lease obligations fin cf | CurrentYTDDuration | -133000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -314000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -378000000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -0 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | － | JPY |
| Proceeds from sales of treasury stock fin cf | Prior1YTDDuration | 55000000 | JPY |
| Proceeds from sales of treasury stock fin cf | CurrentYTDDuration | 57000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -1041000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -937000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 0 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 0 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 491000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 265000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 11618000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 10643000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 12109000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 10908000000 | JPY |
| Haulage expenses sga | Prior1YTDDuration | 135000000 | JPY |
| Haulage expenses sga | CurrentYTDDuration | 152000000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | 1000000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | 0 | JPY |
| Directors compensations sga | Prior1YTDDuration | 198000000 | JPY |
| Directors compensations sga | CurrentYTDDuration | 210000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |